MARLBOROUGH, Mass.–(BUSINESS WIRE) January 30, 2019 –Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for…Original Article
Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)
